Dashnaiv Peptides
Compounds·repair & anti inflammatory·copper-binding tripeptide; wound-healing and gene-expression effects reported

GHK-Cu: topical evidence, injected use, the doses that circulate, side effects and what copper peptide research shows

What 169 indexed publications and 1 randomized trials actually state about ghk-cu, sentence by sentence, each tied to its source and labeled by the kind of evidence it is.

Human clinical trial Reviewed 44 sources Updated Also: Cu-GHK

At a glance

Evidence availability
Human clinical evidence
Strongest tier in the indexed literature
Indexed publications
169
Europe PMC, title or abstract, 2026-09-14
Human studies in ledger
5
1 randomized; study count, not efficacy proof
Approval
none found
no registered development programme
Routes reported
intranasal, intraperitoneal, topical
from studies in this ledger
Studied in
Cattle, Humans, Mice, Swine, Zebrafish
24 primary studies in the evidence table
Reviewed by Adam Mirando, PharmD, on . What changed

What GHK-Cu is and how it acts

GHK-Cu is a peptide in the repair & anti inflammatory class (copper-binding tripeptide; wound-healing and gene-expression effects reported). Europe PMC indexes 169 publications naming it or a listed alias in a title or abstract, including 1 randomized controlled trials and 0 clinical trials of any design, as of . The strongest evidence tier in that literature is human clinical trials.

This page reports what those studies state, sentence by sentence, with each statement tied to its source and labeled by the kind of evidence it is. It does not recommend use, and it does not translate study doses into anything personal.

What the evidence level means

Publication counts show what is indexed, not how strong the evidence is. The ledger below separates human clinical records from preclinical, analytical, and in-vitro work.

Human clinical studies in this ledger51 randomized · 4 other human clinical
Evidence strengthNot yet assessedSeparate from evidence availability
Efficacy signalNot yet assessedRead the study result, not the tier alone

Interpretation boundary: An indexed publication count is a discovery measure. It does not establish efficacy, safety, approval, or a personal treatment plan.

GHK-Cu in two minutes

What it is. A three-amino-acid peptide bound to copper, found naturally in human plasma, isolated in 1973. Its plasma level falls with age. It has been a cosmetic ingredient, the "copper peptide" of skincare, since the 1990s.

What the research actually shows. 169 indexed publications; one randomized trial and a handful of human studies, all of them topical: skin ageing, recovery after laser treatment, scars, scalp flaking, wound gels. Cell and animal work on collagen, healing and gene expression. For injected GHK-Cu, which is what the dosage searches are about, there is no human study.

What people commonly report using. 1 to 2 milligrams injected daily or a few times a week, or topical serums at 1 to 3 percent. Only the second has trials.

Status. Permitted cosmetic ingredient; a cleared wound-dressing device in the 1990s; not an approved drug by any route; not named on the WADA list.

Where the evidence is thinnest. Everything about injection: absorption, dose, effect, safety and copper balance.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

How it works

Written from general pharmacology and the development record, and marked as editorial synthesis; the measurements behind it are quoted in the biomarker section.

  • GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to a copper(II) ion. Loren Pickart isolated it from human plasma in 1973 while studying why young plasma made liver cells behave more youthfully than old plasma. It occurs naturally in plasma, saliva and urine, and its reported plasma concentration falls with age, from roughly 200 nanograms per millilitre at twenty to about 80 at sixty, a decline that underlies most of the ageing claims made for it.Editorial synthesis
    Editorial synthesis from general knowledge
  • Its actions in cell and animal work fall into three groups: delivering copper to enzymes that cross-link collagen and elastin and to antioxidant enzymes; signalling on its own to increase collagen, glycosaminoglycans and growth factors while damping inflammatory signals and tissue-degrading enzymes; and, in computational analyses of gene-expression databases, shifting the activity of a large number of genes toward patterns seen in wound healing and away from those seen in inflammation and some cancers. The gene-expression findings are from database analyses by the compound's discoverer and have not been tested as predictions in people.Editorial synthesis
    Editorial synthesis from general knowledge
  • The human evidence is almost entirely topical: creams and gels on skin and scalp, in trials of photo-ageing, post-laser recovery, wound healing and hair. A copper peptide wound gel was cleared in the United States in the 1990s as a medical device for chronic ulcers. Injectable GHK-Cu, which is what most searchers mean by dosage, has no human trial at all; its use rests on the topical record, the plasma-decline story and the animal work.Editorial synthesis
    Editorial synthesis from general knowledge

What happened in the human studies?

This record's ledger holds 5 primary human studies, of which 2 are trials. Few enough to show in full: each card quotes what its abstract reported about GHK-Cu. Read them before any other section on this page.

  • Clinical trial humans 2026 Human clinical trial
    Clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls.
    Source pmid-42619529 · quoted verbatim from the abstract
  • Randomized controlled trial humans 2006 Human clinical trial
    The results of the questionnaire indicated a significant difference in the posttreatment improvement of overall skin quality for patients using GHK-Cu (P = .04).
    Source pmid-16847171 · quoted verbatim from the abstract
  • Human study humans 2026 Observational, human
    In addition, one face cream formulated with the combination as the sole active ingredients protected human skin explants from ultraviolet irradiation induced damage by maintaining skin morphology and decreasing the degradation of extracellular matrix.
    Source pmid-42573538 · quoted verbatim from the abstract
  • Human study humans 2025 Observational, human
    Digital photographs documented progressive scar visibility reduction.
    Source pmid-41001334 · quoted verbatim from the abstract
  • Human study humans 2024 Observational, human
    As per the ASFS scale for adherent scalp flaking, a significant improvement of 61.24% (p Hamamelis virginiana , hesperidin, hyaluronic acid, and pea protein ( Pisum sativum ) for hydration and overall scalp health over the 15-day treatment period.
    Source pmid-39449909 · quoted verbatim from the abstract

What did the studies find?

Reported outcomes, not benefits. Every human study of GHK-Cu is topical; the injected use that dominates searches has no human study at all. One row per primary study in this record's ledger. Fields are read from each paper's indexing and abstract. "Analytical method" marks papers about detecting or measuring the compound rather than about its effects.

24 primary studies in this record's ledger, strongest evidence first. A dash means the abstract did not state the value.
StudyDesignnSpeciesDoseRouteDurationReported outcomeTier
Mokhtar 2026 Clinical trial — Humans——— Clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and significantly reduced wrinkle volume and depth compared with controls. Human clinical trial
Miller 2006 Randomized controlled trial — Humans——12 weeks The results of the questionnaire indicated a significant difference in the posttreatment improvement of overall skin quality for patients using GHK-Cu (P = .04). Human clinical trial
Wang 2026 Human study — Humans——— In addition, one face cream formulated with the combination as the sole active ingredients protected human skin explants from ultraviolet irradiation induced damage by maintaining skin morphology and decreasing the… Observational, human
Patel 2025 Human study — Humans——— Digital photographs documented progressive scar visibility reduction. Observational, human
Patel 2024 Human study — Humans——15 day As per the ASFS scale for adherent scalp flaking, a significant improvement of 61.24% (p Hamamelis virginiana , hesperidin, hyaluronic acid, and pea protein ( Pisum sativum ) for hydration and overall scalp health over… Observational, human
Sadeqi 2026 Animal study — Swine——— Skin treatment with polymer STAR particles increased intradermal drug delivery by up to 37-fold, depending on the drug type and the STAR particle material and application duration. Animal, preclinical
Hu 2026 Animal study — Zebrafish——— GHK-Cu notably decreased the migration of neutrophils and macrophages, suppressed the expression of pro-inflammatory cytokines (tnf-a, il-1β, il6) and increased the expression of the anti-inflammatory cytokine il-10. Animal, preclinical
Mao 2025 Animal study — Mice——— Discussion This study found that GHK-Cu demonstrated significant therapeutic effects in DSS-induced UC in mice. Animal, preclinical
Tucker 2024 Animal study — Mice15 mg/kgintranasal— Results showed that intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus. Animal, preclinical
Bian 2024 Animal study — Mice——— Its molecular target, peroxiredoxin 6 (PRDX6), has been identified, and GHK-Cu can bind to PRDX6, thus attenuating lung inflammation and fibrosis in silicosis mice without significant systemic toxicity. Animal, preclinical
Liu 2024 Animal study — Mice—topical— Furthermore, the exact effects of the IL-M system on the expression of growth factors, such as vascular endothelial growth factor, were revealed, and it was found that microemulsion increased the activation of the… Animal, preclinical
Rosenfeld 2023 Animal study — Mice——— Sleep-deprived mice treated with GHK did not show the acute learning impairment seen in sleep-deprived mice treated with saline. Animal, preclinical
Deng 2023 Animal study 9 Mice——— GHK-Cu was found to rescue CSE-induced skeletal muscle dysfunction in C2C12 myotubes, as evidenced by increased expression of myosin heavy chain, reduced expression of MuRF1 and atrogin-1, elevated mitochondrial… Animal, preclinical
Zhang 2022 Animal study — Mice—intraperitoneal— GHK-Cu reduced the inflammation and oxidation by decreasing the expression of inflammatory cytokines (IL-1β and TNF-α) in the bronchoalveolar lavage and the enzymatic activity of MPO and MDA in the lung homogenate… Animal, preclinical
Dou 2020 Animal study — Mice——— — Animal, preclinical
Rabenstein 1995 Animal study — Cattle——— As the pD is increased and the carboxylic acid groups are titrated, chemical shift data indicate that ammonium groups of GHK are hydrogen bonded to heparin carboxylate groups, while the histidyl imidazolium ring… Animal, preclinical
Yu 2026 In vitro study — ———— In vitro and in vivo evaluations have confirmed that the HCG@CDs hydrogel effectively alleviates radiation-induced oxidative damage and inflammatory responses, significantly accelerating the healing of skin wounds. Mechanistic, in vitro
Chen 2026 In vitro study — ———— — Mechanistic, in vitro
Huang 2026 In vitro study — ———— The drug-GHK systems exhibited significantly enhanced dissolution performance, including faster dissolution rates, higher drug concentration and sustained supersaturation (up to 1440 min) compared to both the pure… Mechanistic, in vitro
Greco 2025 In vitro study — Humans——— — Mechanistic, in vitro
Dymek 2023 In vitro study — ———— The obtained results confirmed that the liposomes can be used as carriers for biomimetic peptides such as copper-binding peptide and that the GHK-Cu did not significantly affect the tyrosinase activity but led to 48.90… Mechanistic, in vitro
Bossak-Ahmad 2020 In vitro study — Humans——— — Mechanistic, in vitro
Li 2016 In vitro study — Humans——— We determined cell viability and cytotoxicity by using tetrazolium reduction assay and Lactate Dehydrogenase (LDH) assay, performed real-time PCR and protein quantification to assess the expression of biomarkers after… Mechanistic, in vitro
Laussac 1983 In vitro study — Humans——— — Mechanistic, in vitro

What doses did studies use?

The only doses in studies are topical concentrations and animal doses. No human study has tested injected GHK-Cu; the 1 to 2 milligram figures that circulate come from communities and clinics. Each entry is a sentence quoted from the study's abstract, with the study's design, sample size and year in front of it. Comparator doses in the same sentence are not attributed to ghk-cu.

  • Animal study mice 2024 Animal, preclinical
    Doses stated in the abstract: 15 mg/kg
    Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age.
    Source pmid-40766919 · quoted verbatim from the abstract, emphasis added

GHK-Cu dosage chart: topical trials versus injected use

The trials are topical. The dosage searches are about injections. The table keeps the two apart.

Source of the figureDoseScheduleWhat it showed
Topical trials in skin ageing (1998 to 2002)Creams at about 1 to 2%Twice daily, 12 weeksImproved skin thickness, density and wrinkle scores versus vehicle in small trials
Post-laser and scar studies (2025 to 2026)Cosmetic formulationsDaily for weeksFaster recovery and reduced scar visibility, per the indexed abstracts
Wound gel (1990s device clearance)2% copper peptide gelDaily dressingDiabetic and chronic ulcers; cleared as a device
Scalp study (2024)Topical formulation with other activesDailyReduced flaking; GHK-Cu was one of several ingredients
Mouse studies15 mg/kg intranasal; 0.2 to 20 µg/g intraperitonealDays to weeksAlzheimer-model and healing models
Commonly reported, injected1 to 2 mg subcutaneousDaily or 2 to 3 times weekly, 4 to 8 weeksNo human study of any injected dose
Commonly reported, topical1 to 3% serumOnce or twice dailyClosest to the trial evidence

The injected doses that circulate are a thousand times the plasma concentrations the ageing story rests on, delivered by a route no study has used. That is not an argument against them; it is a statement that they came from nowhere in the literature.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

What side effects have been reported?

Events and their frequency as each study reported them, with the denominator where the abstract gives one.

  • Animal study mice 2024 Animal, preclinical
    Copper peptides (GHK-Cu) are a powerful hair growth promoter with minimal side effects when compared with minoxidil and finasteride; however, challenges in delivering GHK-Cu topically limits their non-invasive applications.
    Source pmid-38026438 · quoted verbatim from the abstract

Who GHK-Cu is discussed for, and the cautions that recur

The interest. Skin ageing, hair thinning, scars and healing, on the strength of the topical trials and the plasma-decline story; injection is chosen on the assumption that systemic delivery does more than a serum. Nothing tests that assumption.

Cautions that recur.

  • Wilson's disease and copper-handling disorders. The compound delivers copper; anyone who cannot excrete it should not add it. This is the one caution every source agrees on.
  • Copper balance with repeated injection. Milligram doses for weeks add measurable copper; no study has measured what that does to serum copper, ceruloplasmin or the liver.
  • Blood pressure. Transient light-headedness after injection is a recurring community report; the mechanism is unknown.
  • Cancer. The gene-expression analyses suggest activity against some cancer-related patterns, and the compound promotes growth factors and blood vessels; both directions are theoretical and untested.
  • Topical sensitivity. Contact irritation with serums, and interactions with vitamin C and acid products that can strip the copper from the peptide.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Biomarkers measured in studies

Laboratory and clinical measures the studies report tracking, including which hormones did and did not change.

  • Human study humans 2026 Observational, human
    The combination outperformed TBFE or GHK-Cu alone in inhibiting secretion of inflammatory cytokines by lipopolysaccharide-stimulated macrophages.
    Source pmid-42573538 · quoted verbatim from the abstract
  • Human study humans 2024 Observational, human
    This study aimed to evaluate the safety, efficacy, and tolerability of a novel regimen combining a scalp scrub with hydroxy acid derivatives for exfoliation and dandruff removal, and a serum containing copper tripeptide-1, witch hazel ( Hamamelis virginiana) , hesperidin, hyaluronic acid, and pea protein ( Pisum sativum ) for hydration and scalp health.
    Source pmid-39449909 · quoted verbatim from the abstract
  • Animal study zebrafish 2026 Animal, preclinical
    GHK-Cu notably decreased the migration of neutrophils and macrophages, suppressed the expression of pro-inflammatory cytokines (tnf-a, il-1β, il6) and increased the expression of the anti-inflammatory cytokine il-10.
    Source pmid-41997403 · quoted verbatim from the abstract
  • Animal study mice 2025 Animal, preclinical
    GHK-Cu alleviated weight loss, improved the disease activity index (DAI), reduced colonic edema and shortening, attenuated inflammatory damage, increased goblet cell numbers, suppressed inflammatory cytokines such as TNF-α, IL-6, and IL-1β, and promoted mucosal repair.
    Source pmid-40672369 · quoted verbatim from the abstract
  • Animal study mice 2024 Animal, preclinical
    Copper peptides (GHK-Cu) are a powerful hair growth promoter with minimal side effects when compared with minoxidil and finasteride; however, challenges in delivering GHK-Cu topically limits their non-invasive applications.
    Source pmid-38026438 · quoted verbatim from the abstract
  • Animal study mice 2022 Animal, preclinical
    GHK-Cu was injected intraperitoneally at doses of 0.2, 2 and 20 μg/g/day in 100 µl of saline on alternative days from the 1st day after CS exposure.
    Source pmid-35936787 · quoted verbatim from the abstract

Reported interactions

Sentences in which the compound is studied alongside another agent. Read the quotation: the word interaction can also be statistical.

  • Human study humans 2026 Observational, human
    The present study aims to explore the skin protective effects of a novel extract of ferment in combination with copper tripeptide-1 GHK-Cu from an anti-inflammation perspective.
    Source pmid-42573538 · quoted verbatim from the abstract
  • Animal study rats 2026 Animal, preclinical
    Three independent reviewers searched the PubMed database using permutations of peptide search terms (BPC-157, TB-500, CJC-1295, MK-677 [ibutamoren], ipamorelin, and GHK-Cu) combined with musculoskeletal tissue search terms (bone, fracture, muscle, tendon, ligament, meniscus, and cartilage) following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
    Source pmid-42578445 · quoted verbatim from the abstract
  • In vitro study 2023 Mechanistic, in vitro
    Anionic (AL) and cationic (CL) hydrogenated lecithin-based liposomes were obtained as GHK-Cu skin delivery systems using the thin-film hydration method combined with freeze-thaw cycles and the extrusion process.
    Source pmid-37896245 · quoted verbatim from the abstract
  • In vitro study humans 1981 Mechanistic, in vitro
    The interaction between Cu(II) and the growth-modulating tripeptide glycyl-L-histidyl-L-lysine in the presence and absence of L-histidine was investigated by potentiometric titration and visible-absorption spectrophotometry at 25 degrees C in 0.15 M-NaCl.
    Source pmid-7340824 · quoted verbatim from the abstract

What happens after a dose, and what people report over weeks

Measured. In the topical trials, changes in skin measurements appeared over twelve weeks of twice-daily use. Nothing is measured after injection in people.

Commonly reported, untested. From injection, users describe improved skin texture within two to four weeks and hair changes over two to three months; before-and-after photographs circulate without controls, lighting standards or blinding, in a domain where such photographs are notoriously unreliable.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Escalation schedules used in studies

How trials stepped doses, reported as study design.

  • In vitro study humans 1981 Mechanistic, in vitro
    The interaction between Cu(II) and the growth-modulating tripeptide glycyl-L-histidyl-L-lysine in the presence and absence of L-histidine was investigated by potentiometric titration and visible-absorption spectrophotometry at 25 degrees C in 0.15 M-NaCl.
    Source pmid-7340824 · quoted verbatim from the abstract

Study durations

Treatment and follow-up periods as stated in each abstract.

  • Randomized controlled trial humans 2006 Human clinical trial
    Durations stated: 12 weeks
    In addition, overall improvement in wrinkles and overall improvement in skin appearance 12 weeks after treatment were assessed.
    Source pmid-16847171 · quoted verbatim from the abstract, emphasis added
  • Human study humans 2024 Observational, human
    Durations stated: 15 day
    As per the ASFS scale for adherent scalp flaking, a significant improvement of 61.24% (p Hamamelis virginiana , hesperidin, hyaluronic acid, and pea protein ( Pisum sativum ) for hydration and overall scalp health over the 15-day treatment period.
    Source pmid-39449909 · quoted verbatim from the abstract

Routes studied

Routes of administration named in each study.

  • Animal study mice 2024 Animal, preclinical
    administration by intranasal route reported
    Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age.
    Source pmid-40766919 · quoted verbatim from the abstract
  • Animal study mice 2024 Animal, preclinical
    administration by topical route reported
    Copper peptides (GHK-Cu) are a powerful hair growth promoter with minimal side effects when compared with minoxidil and finasteride; however, challenges in delivering GHK-Cu topically limits their non-invasive applications.
    Source pmid-38026438 · quoted verbatim from the abstract
  • Animal study mice 2022 Animal, preclinical
    administration by intraperitoneal route reported
    GHK-Cu was injected intraperitoneally at doses of 0.2, 2 and 20 μg/g/day in 100 µl of saline on alternative days from the 1st day after CS exposure.
    Source pmid-35936787 · quoted verbatim from the abstract

Weight-normalized doses, as published

Per-kilogram figures exactly as each study published them, for the species it studied.

  • Animal study mice 2024 Animal, preclinical
    Weight-normalized doses as published: 15 mg/kg
    Male and female 5xFAD transgenic mice on the C57BL/6J background at 4 months of age were given 15 mg/kg GHK-Cu intranasally 3 times per week for 3 months until 7 months of age.
    Source pmid-40766919 · quoted verbatim from the abstract, emphasis added

Weight-normalized figures above are reproduced exactly as each study published them, for the species it studied. Dose does not scale linearly with body mass between species: metabolic rate, clearance and receptor density differ, and regulatory guidance uses allometric, not proportional, conversion. A mg/kg figure from a rat study is a fact about that rat study and nothing else.

What people report outside the literature

What circulates in user communities and clinic marketing, reported so a reader knows the figures and their origin. None of it has been tested in a trial, and none of it is a suggestion.

  • Outside the literature, injectable GHK-Cu circulates at 1 to 2 milligrams by subcutaneous injection daily, or two to three times a week, for four to eight weeks, often near skin or hair the user wants to change; intranasal use appears too, borrowed from a mouse study. Topically, cosmetic serums at 1 to 3 percent are applied once or twice daily, and this is the one form with human trials behind it. The 'GLOW stack' adds BPC-157 and TB-500. None of the injected figures has been tested in a human study.Editorial synthesis
    Editorial synthesis from general knowledge
  • Effects people report from injection are firmer skin, thicker hair, faster healing of minor injuries and reduced joint discomfort; reported side effects are pain and bruising at the injection site, transient nausea, light-headedness or a drop in blood pressure shortly after injecting, and a metallic taste. Long-term effects of injecting a copper complex, including on copper balance, have not been studied. From topical use, irritation and contact sensitivity are the reported issues.Editorial synthesis
    Editorial synthesis from general knowledge

Reconstituting GHK-Cu: concentrations for common vial sizes

Injectable GHK-Cu is sold as a blue powder dissolved before use. The arithmetic is exact; the choice of what to draw is not made here.

VialDiluent addedConcentrationVolume holding 1 mg on a U-100 syringe
50 mg2 mL25,000 µg/mL0.04 mL (4 units)
50 mg5 mL10,000 µg/mL0.10 mL (10 units)
100 mg5 mL20,000 µg/mL0.05 mL (5 units)
100 mg10 mL10,000 µg/mL0.10 mL (10 units)

Vials are large because the circulating doses are in milligrams, not micrograms; a 50 mg vial at 2 mL gives a very concentrated solution and small volumes that are easy to misread on a syringe. The solution is blue from the copper. A change in colour toward green or brown suggests the copper has come out of the complex. The reconstitution calculator shows its formula.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Method note · shared across compounds

Reconstitution mathematics

Lyophilised peptide is supplied as a mass in a vial and dissolved in a stated volume of diluent. Two figures follow from that and nothing else:

  • Concentration = mass in vial ÷ diluent volume. A 5 mg vial in 2 mL is 2.5 mg/mL, or 2,500 mcg/mL.
  • Volume for a given mass = that mass ÷ concentration. 250 mcg at 2,500 mcg/mL is 0.1 mL. On a U-100 insulin syringe, where 1 mL is 100 units, that is 10 units.

Study doses on this page are quoted as published, in the units the authors used. Converting between mcg, mg and IU, or between a mass and a syringe volume, is arithmetic; deciding a mass is not, and this page does not do it. The reconstitution calculator performs the conversion with the formula shown.

Method note · shared across compounds

Reading a certificate of analysis

A certificate of analysis is a laboratory report on one batch. Reading it means checking four things in order.

  1. Identity. Mass spectrometry should report an observed molecular mass matching the peptide's theoretical mass within the instrument's stated tolerance. A certificate with no mass spectrometry, or one that lists only the expected value, has not confirmed identity.
  2. Purity. HPLC purity is the area of the main peak as a share of all peaks, at a stated wavelength. It says nothing about what the other peaks are, and it is not a measure of quantity.
  3. Quantity. Net peptide content, by amino acid analysis or UV, is the fraction of the vial's mass that is peptide rather than counter-ions and water. A 5 mg vial at 80% net content holds 4 mg of peptide, and every concentration figure above changes accordingly.
  4. Provenance. The batch number on the certificate should match the vial, the laboratory should be named and independent of the seller, and the test date should be recent.

This page rates no supplier and links to none. It describes how to read the document.

Method note · shared across compounds

Equipment described in studies

Published human studies of injectable peptides report the same small set of materials: single-use insulin syringes with fixed needles, most often U-100 with 29 to 31 gauge needles; bacteriostatic water or sterile water for injection as diluent, with the choice stated in the methods; alcohol swabs; and refrigerated storage of reconstituted solution. Animal studies more often report intraperitoneal or intragastric administration and state the vehicle used. Where a study in this record's ledger names its materials or vehicle, that sentence appears under storage or routes above; where it does not, nothing is assumed here.

Storage and handling

Powder is refrigerated or frozen, protected from light. Reconstituted solution is refrigerated and typically used within about four weeks; the blue colour should persist, and a shift toward green or brown, or any cloudiness, is a reason to discard it. Topical products follow their own labels; copper peptides are unstable alongside strong acids and high-dose vitamin C, which is why formulators separate them.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Blood tests and monitoring that would be relevant

Nothing has been validated for GHK-Cu. Given what it delivers, these are the measures a clinician would consider for repeated injection.

MeasureWhy it appearsWhen
Serum copper and ceruloplasminThe compound delivers copper; excess accumulates in liver and brainBaseline and after a course
Liver enzymesCopper is handled by the liverBaseline and after a course
Blood pressurePost-injection light-headedness is a recurring reportAround injections
ZincCopper and zinc compete for absorption and bindingBaseline

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Common mistakes in how GHK-Cu is discussed

  • Applying topical evidence to injections. Every human trial is a cream, gel or serum.
  • Reading the gene-expression analyses as clinical results. They are database computations, largely by the compound's discoverer, and untested as predictions.
  • Treating "natural" and "declines with age" as proof that replacing it helps. Many things decline with age; the inference has been tested for none of them by injection.
  • Combining it with acids or vitamin C on the skin. The copper leaves the peptide.
  • Assuming the "GLOW stack" was studied. The BPC-157, TB-500 and GHK-Cu combination has no study; each component's evidence is what it is.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

GHK-Cu vs BPC-157, TB-500 and KPV

The compounds it is combined with in the healing and skin stacks. GHK-Cu is the only one with human trials in its own class, and all of them are topical.

CompoundMechanism (proposed)Human evidenceStatus
GHK-CuCopper-binding tripeptide; collagen, growth factors, gene expressionTopical trials in skin ageing, scars, wounds, scalp; none injectedCosmetic ingredient; wound-device clearance; not a drug
BPC-157Gastric-protein fragment; nitric oxide, growth-factor receptors3 uncontrolled pilots; otherwise ratsNot approved; FDA compounding Category 2; WADA S0
TB-500Thymosin β4 fragment; actin binding, cell migrationTrials of the parent protein in eyes and woundsNot approved; WADA S2
KPVα-MSH fragment; anti-inflammatoryAnimal and cell studiesNot approved

Class peers with their own records: BPC-157, TB-500, KPV; the repair and anti-inflammatory class page lists them together.

Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.

Exclusion criteria in studies

Who each trial excluded, as stated in the abstract.

  • Clinical trial humans 2026 Human clinical trial
    Eligible studies included clinical and preclinical models investigating GHK-Cu as a standalone intervention for aesthetic applications.
    Source pmid-42619529 · quoted verbatim from the abstract

Other compounds in its class

Same class in the registry: BPC-157, KPV, TB-500. Each row shows what that compound's own record states; nothing is inferred across rows.

4 compounds in the repair & anti inflammatory class. Each row states what that compound's own record says; nothing is inferred across rows.
CompoundTierPublicationsRCTsRecord
GHK-Cu Human clinical trial 169 1 draft
BPC-157 Observational, human 228 0 draft
KPV Animal, preclinical 138 0 draft
TB-500 Human clinical trial 1,257 7 draft

Studied in combination

Whether any indexed study tested GHK-Cu together with the compounds it is commonly combined with. A count of zero is the finding, not a gap in this page.

Regulatory status

Registry facts only. Jurisdiction-level status, compounding categories and sport prohibitions need their own cited documents before they appear here.

  • GHK-Cu is a cosmetic ingredient (INCI name copper tripeptide-1) permitted in skincare in most jurisdictions, and a copper peptide gel was cleared in the United States in the 1990s as a wound-dressing device. As a drug, in any route, it is not approved anywhere. Injectable products are sold as research chemicals. It is not named on the WADA Prohibited List.Editorial synthesis
    Editorial synthesis from general knowledge · primary document to be added to the ledger

Open questions and limitations

What is genuinely unknown, stated plainly. A missing field is not evidence that the outcome is safe, effective, or established.

  • No study in this record's ledger reports onset or duration of effects for GHK-Cu.

Questions people ask

Does GHK-Cu regrow hair?

Copper peptides have small topical studies and animal work on follicles; the indexed scalp study measured flaking with GHK-Cu among several ingredients. No trial shows regrowth from injected GHK-Cu.

What is GHK-Cu?

A three-amino-acid peptide, glycyl-histidyl-lysine, bound to copper, found naturally in human plasma and isolated in 1973. It is the copper peptide of skincare and, more recently, an injected research chemical.

What does GHK-Cu do?

In cells and animals it delivers copper to collagen-building and antioxidant enzymes, increases collagen and growth factors, damps inflammatory signals, and shifts gene expression in database analyses. In human trials, all topical, it improved skin measurements, post-laser recovery, scars and scalp flaking.

What is the GHK-Cu injection dose?

No human study has tested injected GHK-Cu at any dose. The 1 to 2 milligram daily or thrice-weekly figures that circulate come from communities and clinics.

Is GHK-Cu better topical or injected?

The evidence exists only for topical use. Injection assumes systemic delivery does more, and nothing has tested that assumption.

What are the side effects of GHK-Cu?

Topically: irritation and contact sensitivity. Injected, per community reports: injection-site pain and bruising, nausea, light-headedness or a drop in blood pressure, metallic taste. Long-term effects of injecting copper, including on copper balance, are unstudied.

Is GHK-Cu FDA approved?

Not as a drug by any route. It is a permitted cosmetic ingredient, and a copper peptide wound gel was cleared as a medical device in the 1990s.

Who should avoid GHK-Cu?

Anyone with Wilson's disease or another copper-handling disorder, since the compound delivers copper. Beyond that, the cautions are theoretical: copper balance with repeated injection, blood pressure, and unstudied effects in cancer.

How is GHK-Cu reconstituted?

Powder dissolved in bacteriostatic water; a 50 mg vial in 5 mL gives 10 mg per mL, so 1 mg is 0.1 mL. The solution is blue; a shift to green or brown means the copper has left the complex.

How long does GHK-Cu take to work?

In topical trials, skin measurements changed over twelve weeks. For injection, nothing is measured; users report skin changes in weeks and hair changes in months, from uncontrolled photographs.

Does GHK-Cu regrow hair?

Copper peptides have small topical studies and animal work on hair follicles; the one indexed scalp study measured flaking with GHK-Cu among several ingredients. No trial shows hair regrowth from injected GHK-Cu.

What is the GLOW stack?

A community name for GHK-Cu combined with BPC-157 and TB-500, aimed at skin and healing. No study has tested the combination; the stack page holds what exists for each component.

Can GHK-Cu be combined with BPC-157 and TB-500?

Communities do. Each component has its own evidence, none of it for the combination.

Is GHK-Cu banned in sport?

It is not named on the WADA Prohibited List.

Does GHK-Cu decline with age?

Its reported plasma level falls from about 200 nanograms per millilitre at twenty to about 80 at sixty. That decline is the basis of the ageing claims; whether replacing it by injection does anything has not been tested.

Can GHK-Cu be used with vitamin C or retinol?

Strong acids and high-dose vitamin C can strip the copper from the peptide on the skin, which is why formulators separate them. Retinol is usually alternated rather than layered, on formulation grounds.

How should GHK-Cu be stored?

Powder refrigerated or frozen, away from light; reconstituted solution refrigerated and used within about four weeks, discarded if it loses its blue colour or clouds.

Sources

Full citations. Every claim above links to one of these by its id.

  1. 1
  2. 2
    The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
    pmid-42619529 · · peer-reviewed
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
Show the remaining 32 sources
  1. 13
  2. 14
  3. 15
  4. 16
  5. 17
  6. 18
  7. 19
  8. 20
  9. 21
  10. 22
  11. 23
  12. 24
  13. 25
  14. 26
  15. 27
  16. 28
  17. 29
  18. 30
  19. 31
  20. 32
  21. 33
    The potential of GHK as an anti-aging peptide.
    pmid-35083444 · · peer-reviewed
  22. 34
  23. 35
  24. 36
  25. 37
  26. 38
  27. 39
    The human tri-peptide GHK and tissue remodeling.
    pmid-18644225 · · peer-reviewed
  28. 40
  29. 41
  30. 42
  31. 43
  32. 44

Reference card

Reference card · generated /compounds/ghk-cu
Compound
GHK-Cu, repair and anti inflammatory
Evidence tier
Human clinical trial
Indexed publications
169 · 1 RCTs · 0 other clinical trials
Approval
no registered development programme found
Routes reported
intranasal, intraperitoneal, topical
Reviewed
Adam Mirando, PharmD,

Study figures are as published in each source and are not recommendations. Print or save this card with its date.

Last reviewed and what changed

Newest first. These are the record's own revision dates, and the same dates feed the sitemap.

  1. · Reviewed by Adam Mirando, PharmD, on 2026-09-25.
  2. · Misattribution check: evidence_table (pmid-42578445): a review's collective sentence about six peptides is not one compound's evidence row. The sources stay in the ledger; only the claims that put another agent's result under this compound were removed.
  3. · Written guide (9 sections), FAQ to 16, mechanism, reported-use and regulatory editorial sections, intent-driven H1 and title; the topical-versus-injected distinction made explicit throughout. Fourth compound through the loop.
  4. · Claims drafted extractively from 37 ledger sources by scripts/draft_claims.py: 21 claims, 25 evidence-table rows. Status researched -> draft.
  5. · Claims drafted extractively from 37 ledger sources by scripts/draft_claims.py: 33 claims, 25 evidence-table rows. Status researched -> draft.
  6. · Claims drafted extractively from 37 ledger sources by scripts/draft_claims.py: 42 claims, 25 evidence-table rows. Status researched -> draft.
  7. · Metadata refreshed by scripts/fetch_evidence.py --refresh-meta: tier animal-preclinical -> human-clinical-trial.
  8. · Evidence fetched from Europe PMC and ChEMBL by scripts/fetch_evidence.py; claims not yet written.